Related Experiment Video
Updated: Aug 1, 2025
Evaluation of Antimicrobial Activities of Nanoparticles and Nanostructured Surfaces In Vitro
Published on: April 21, 2023
Evaluation of the Antibacterial Activity of Quinoxaline Derivative Compound Against Methicillin-Resistant
Abdelbagi Elfadil1,2, Ahmad Mandeel Alzahrani1, Hani Abdullah1
1Department of Clinical Microbiology and Immunology, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia.
Background:
While the frequency of methicillin-resistant Staphylococcus aureus (MRSA) continues to rise globally, there is a fear regarding an increase in vancomycin resistance among S. aureus strains. As far back as the 1960s, MRSA was one of the world's most prevalent antibiotic-resistant bacteria. Among hospitalized patients and community members, MRSA is the cause of a significant number of infections. As a result of its resistance to classical beta-lactam and, in some cases, vancomycin antibiotics, efforts must be made as soon as feasible to find a new approach to fighting MRSA.
Purpose:
This study is designed to evaluate the antibacterial activity of quinoxaline derivative compound against MRSA in comparison with vancomycin as a reference drug.
Methods:
Sixty MRSA isolates were subjected to susceptibility testing by broth microdilution method for quinoxaline derivative compound and vancomycin. Each drug's minimal inhibitory concentration (MIC) was determined and compared.
Results:
Among the sixty MRSA isolates, most of the quinoxaline derivative compound MIC findings (56.7%) were 4 µg/mL compared to vancomycin MIC values (63.3%) of 4 µg/mL. In comparison, 20% of quinoxaline derivative compound MIC readings were 2 µg/mL, while the vancomycin MIC results were 6.7%. However, the overall proportion of MIC readings at ≤2 µg/mL for both antibacterial agents was equal (23.3%). None of the isolates were resistant to vancomycin.
Conclusion:
This experiment revealed that most MRSA isolates were associated with low MICs (1-4 μg/mL) for quinoxaline derivative compound. Overall, the susceptibility of the quinoxaline derivative compound signifies a promising efficacy against MRSA and may set a novel treatment approach.
Insights
A novel quinoxaline derivative compound shows promising antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA). This new agent may offer a potential alternative treatment for MRSA infections, addressing rising antibiotic resistance concerns.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) is a growing global health concern, causing significant infections in both hospital and community settings.
- The increasing prevalence of antibiotic resistance, including potential vancomycin resistance in S. aureus, necessitates the development of novel therapeutic strategies.
- MRSA's resistance to conventional antibiotics like beta-lactams and sometimes vancomycin highlights the urgent need for alternative treatments.
Purpose of the Study:
- To evaluate the antibacterial efficacy of a quinoxaline derivative compound against MRSA.
- To compare the activity of the quinoxaline derivative compound with vancomycin, a standard treatment for MRSA infections.
Main Methods:
- The study involved susceptibility testing of sixty MRSA isolates using the broth microdilution method.
- Minimal Inhibitory Concentrations (MICs) for both the quinoxaline derivative compound and vancomycin were determined and compared.
Main Results:
- The quinoxaline derivative compound demonstrated favorable MIC values, with 56.7% of isolates showing an MIC of 4 µg/mL.
- A significant percentage (20%) of MRSA isolates exhibited MICs of 2 µg/mL for the quinoxaline derivative compound.
- The overall proportion of isolates with MICs ≤2 µg/mL was comparable for both the quinoxaline derivative compound and vancomycin (23.3%).
Conclusions:
- The quinoxaline derivative compound exhibited low MICs (1-4 μg/mL) against the majority of MRSA isolates tested.
- The observed susceptibility indicates promising efficacy of the quinoxaline derivative compound as a potential new treatment for MRSA infections.
- This compound represents a potential novel therapeutic approach to combat MRSA, addressing the challenge of antibiotic resistance.
Related Concept Videos
01:28Antimicrobial Effectiveness
01:28Gene Regulation in Microbial Communities: Quorum Sensing